상세 보기
Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/ mTNBC): Final results from the phase Ib/II BEGONIA study
- Schmid, P.;
- Wang, H. C.;
- Lynce, F.;
- Park, Y. H.;
- Ma, C. X.;
- 외 13명
Citations
WEB OF SCIENCE
1- 제목
- Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/ mTNBC): Final results from the phase Ib/II BEGONIA study
- 저자
- Schmid, P.; Wang, H. C.; Lynce, F.; Park, Y. H.; Ma, C. X.; Jung, K. H.; Chen, S. C.; Hou, M. F.; Prady, C.; Tseng, L-M.; Asselah, J.; Wysocki, P. J.; Lord, S.; Rao-Melacini, P.; Stewart, R.; Warzyszynska, K.; Vukovic, P.; Im, S. A.
- 발행일
- 2025-09
- 유형
- Meeting Abstract
- 권
- 36